Final planned overall survival (OS) from OPTiM, a randomized Phase III trial of talimogene laherparepvec (T-VEC) versus GM-CSF for the treatment of unresected stage IIIB/C/IV melanoma (NCT00769704). (6th November 2014) - Andtbacka, Robert HI; Collichio, Frances A; Amatruda, Thomas; Senzer, Neil; Chesney, Jason; Delman, Keith; Spitler, Lynn; Puzanov, Igor; Agarwala, Sanjiv; Milhem, Mohammed; Harrington, Kevin; Middleton, Mark; et al.